Licensed provider review·support@lumoramd.com·Log in
← Medications
MedicationGrowth Hormone Support

Tesamorelin.

A growth hormone-releasing peptide that specifically targets visceral abdominal fat.

Pricing is shown after your free assessment, before you commit.

Start provider review

Free to start. No card required.

Is this for you?

This is for you if

  • Adults who struggle with midsection weight despite diet and exercise
  • Patients wanting body recomposition (fat loss with lean mass preservation)
  • Patients with poor sleep, fatigue, or slow recovery
  • Patients wanting visible improvements in abdominal composition

This isn't for you if

May cause injection-site reactions, mild fluid retention, or joint discomfort. Not appropriate with active cancer, during pregnancy, or with certain pituitary disorders. Baseline labs required.

What it is

Tesamorelin

Tesamorelin is an FDA-approved GHRH analog that supports the body's nighttime growth hormone pulse. It is the peptide with the strongest evidence for targeting visceral fat — the deep abdominal fat surrounding the organs that is most associated with metabolic risk.

How it works

Mechanism and fit.

Tesamorelin signals the pituitary to release growth hormone in its natural rhythm. This drives fat metabolism (particularly visceral fat), supports muscle preservation, and improves sleep and recovery. Patients typically notice that the midsection responds in a way it had not before.

When it may fit

Who this is typically for.

  • Adults who struggle with midsection weight despite diet and exercise
  • Patients wanting body recomposition (fat loss with lean mass preservation)
  • Patients with poor sleep, fatigue, or slow recovery
  • Patients wanting visible improvements in abdominal composition
Tesamorelin - common questions

What patients
most often ask.

Why does tesamorelin specifically target belly fat?+

Tesamorelin's GH pulse is particularly effective at mobilizing visceral fat — the deeper abdominal fat that sits around organs and is most associated with metabolic risk. This is what differentiates it from other GH-axis peptides.

Will I lose muscle?+

No — tesamorelin supports lean mass while targeting fat. It's used in true body recomposition rather than simple weight loss.

When it may fit

Who this is typically for.

These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.

  • <ul><li>Adults who struggle with midsection weight despite diet and exercise</li><li>Patients wanting body recomposition (fat loss with lean mass preservation)</li><li>Patients with poor sleep, fatigue, or slow recovery</li><li>Patients wanting visible improvements in abdominal composition</li></ul>
Provider plan

How this option
is evaluated.

The plan is provider-determined after reviewing your assessment and safety factors.

  • DosingNightly, typically 5 nights on / 2 nights off, 30–60 minutes before bed.
  • Typical duration2–3 months with consistency; optimal results at 8–12 weeks.
  • Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
How care works
  • A licensed provider reviews your assessment before any treatment is recommended.
  • You see full pricing - visit fees, medication, labs, follow-up - before you commit.
  • Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
  • Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.

Start with
provider review.

If you are considering Tesamorelin, the first step is a free assessment. A provider determines whether it fits your goals and medical history.

A provider determines whether treatment is clinically appropriate.

Important information
Lumora may prescribe FDA-approved or compounded medications when clinically appropriate. Compounded medications are not approved by the FDA and are dispensed by a licensed pharmacy under the supervision of a licensed provider.